Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vanda Pharmaceuticals Inc. (VNDA)
USD5.86
+0.01 (+0.17%)
US NASDAQ Healthcare Biotechnology
Address
2200 Pennsylvania Avenue NW 20037
Washington, DC, US
Washington, DC, US
CEO
Mihael H. Polymeropoulos
Website
vandapharma.com
IPO
2006-04-12
CIK 1347178 ISIN US9216591084
Description
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.86
+0.01 (+0.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.60
Float Shares
53.27M
Free Float %
90.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.39% | -8.42% | -11.08% | +4.90% | +45.58% | -27.21% | +59.31% | +2.23% | -63.93% | -21.99% | -33.68% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (19 ratings, all time)
Buy
Price Targets & DCF
Current price
5.86
Low
7.50
+28.0%
Consensus
14.25
+143.2%
Median
14.25
+143.2%
High
21.00
+258.4%
Ratings Trend (MoM)
80% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 1 |
24.00
+309.6%
|
| Last Year | 4 |
16.13
+175.3%
|
| All Time | 5 |
15.10
+157.7%
|
Quality scores
Altman Z-Score
-0.20
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+8.7% ★ Q1'26: +3.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-1,068.8% Q1'26: -64.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-98.9% Q1'26: -97.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-70.0% Q1'26: -97.1% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-199.0% Q1'26: -219.5% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.3% ★ Q1'26: +1.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.09× Q1'26: -0.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2010 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 4 Rev. Ana. 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 3 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
35.22M
est: 76.53B (-100.0%)
|
32.73M
est: 56.54M (-42.1%)
|
33.88M
est: 53.09M (-36.2%)
|
50.16M
est: 178.92M (-72.0%)
|
109.93M
est: 109.37M (+0.5%)
|
146.02M
est: 146.10M (-0.1%)
|
165.08M
est: 164.84M (+0.1%)
|
193.12M
est: 191.62M (+0.8%)
|
227.19M
est: 225.80M (+0.6%)
|
248.17M
est: 244.50M (+1.5%)
|
268.68M
est: 270.72M (-0.8%)
|
254.38M
est: 257.50M (-1.2%)
|
192.64M
est: 182.02M (+5.8%)
|
198.77M
est: 199.45M (-0.3%)
|
216.11M
est: 218.27M (-1.0%)
|
262.72M
260.61M – 264.82M
+20.4% YoY
|
356.32M
318.86M – 393.78M
+35.6% YoY
|
425.37M
421.88M – 428.86M
+19.4% YoY
|
509.07M
479.16M – 537.17M
+19.7% YoY
|
563.83M
530.71M – 594.96M
+10.8% YoY
|
| EBITDA |
10.67M
est: 22.56M (-52.7%)
|
-27.05M
est: -25.09M (-7.8%)
|
-19.27M
est: -21.07M (+8.5%)
|
-54.77M
est: 27.67M (-298.0%)
|
-26.63M
est: -22.75M (-17.0%)
|
-6.70M
est: -1.43M (-367.2%)
|
-13.92M
est: -14.56M (+4.4%)
|
24.69M
est: 4.67M (+429.1%)
|
25.70M
est: 5.50M (+367.3%)
|
34.52M
est: 5.96M (+479.7%)
|
45.01M
est: 45.53M (-1.1%)
|
9.06M
est: -20.20M (+144.9%)
|
-10.94M
est: -24.09M (+54.6%)
|
-32.53M
est: -26.39M (-23.2%)
|
-139.25M
est: -28.89M (-382.1%)
|
-34.77M
-35.05M – -34.49M
-20.4% YoY
|
-47.15M
-52.11M – -42.20M
-35.6% YoY
|
-56.29M
-56.75M – -55.83M
-19.4% YoY
|
-67.37M
-71.09M – -63.41M
-19.7% YoY
|
-74.62M
-78.73M – -70.23M
-10.8% YoY
|
| EBIT |
8.84M
est: 16.84M (-47.5%)
|
-29.18M
est: -27.72M (-5.2%)
|
-21.20M
est: -23.59M (+10.1%)
|
-57.55M
est: 24.40M (-335.9%)
|
-40.19M
est: -36.57M (-9.9%)
|
-18.57M
est: -18.55M (-0.1%)
|
-16.90M
est: -20.61M (+18.0%)
|
21.74M
est: 189.50M (-88.5%)
|
22.81M
est: 1.46M (+1,459.6%)
|
31.66M
est: 1.58M (+1,898.8%)
|
42.17M
est: 42.53M (-0.9%)
|
6.33M
est: -26.71M (+123.7%)
|
-13.95M
est: -28.93M (+51.8%)
|
-40.66M
est: -31.70M (-28.3%)
|
-151.17M
est: -34.69M (-335.8%)
|
-41.76M
-42.09M – -41.42M
-20.4% YoY
|
-56.63M
-62.59M – -50.68M
-35.6% YoY
|
-67.61M
-68.16M – -67.05M
-19.4% YoY
|
-80.91M
-85.38M – -76.16M
-19.7% YoY
|
-89.61M
-94.56M – -84.35M
-10.8% YoY
|
| Net Income |
7.19M
est: 19.29M (-62.7%)
|
-27.66M
est: -27.19M (-1.8%)
|
-20.26M
est: -23.42M (+13.5%)
|
20.19M
est: 24.53M (-17.7%)
|
-39.87M
est: -36.26M (-9.9%)
|
-18.01M
est: -17.77M (-1.3%)
|
-15.57M
est: -18.78M (+17.1%)
|
25.21M
est: 216.25M (-88.3%)
|
115.55M
est: 68.62M (+68.4%)
|
23.34M
est: 26.76M (-12.8%)
|
33.15M
est: 33.12M (+0.1%)
|
6.28M
est: 14.90M (-57.9%)
|
2.51M
est: -10.93M (+123.0%)
|
-18.90M
est: -17.20M (-9.9%)
|
-220.47M
est: -143.44M (-53.7%)
|
-144.78M
-159.38M – -100.37M
-0.9% YoY
|
-64.39M
-89.46M – -29.14M
+55.5% YoY
|
-44.67M
-47.81M – -16.32M
+30.6% YoY
|
-3.14M
-3.37M – -2.90M
+93.0% YoY
|
39.88M
36.83M – 42.74M
+1,368.8% YoY
|
| SGA |
10.15M
est: 34.03M (-70.2%)
|
13.88M
est: 15.22M (-8.8%)
|
24.59M
est: 29.96M (-17.9%)
|
84.64M
est: 90.22M (-6.2%)
|
84.53M
est: 93.42M (-9.5%)
|
99.79M
est: 84.36M (+18.3%)
|
123.84M
est: 95.18M (+30.1%)
|
105.75M
est: 110.64M (-4.4%)
|
129.74M
est: 130.38M (-0.5%)
|
140.51M
est: 141.17M (-0.5%)
|
124.05M
est: 122.63M (+1.2%)
|
136.49M
est: 148.68M (-8.2%)
|
112.88M
est: 124.57M (-9.4%)
|
146.41M
est: 136.50M (+7.3%)
|
237.95M
est: 149.38M (+59.3%)
|
179.80M
178.36M – 181.24M
+20.4% YoY
|
243.86M
218.22M – 269.49M
+35.6% YoY
|
291.11M
288.72M – 293.50M
+19.4% YoY
|
348.39M
327.93M – 367.62M
+19.7% YoY
|
385.87M
363.21M – 407.17M
+10.8% YoY
|
| EPS |
0.26
est: 0.21 (+26.8%)
|
-0.98
est: -0.87 (-12.6%)
|
-0.67
est: -1.21 (+44.4%)
|
0.58
est: -1.89 (+130.8%)
|
-0.94
est: -0.57 (-63.8%)
|
-0.41
est: -0.03 (-1,390.9%)
|
-0.35
est: -0.20 (-71.6%)
|
0.50
est: 0.30 (+66.7%)
|
2.17
est: 1.18 (+83.9%)
|
0.43
est: 0.46 (-6.6%)
|
0.60
est: 0.56 (+8.1%)
|
0.11
est: 0.05 (+120.0%)
|
0.04
est: -0.19 (+123.1%)
|
-0.32
est: -0.32 (-1.1%)
|
-3.74
est: -2.67 (-39.9%)
|
-2.30
-2.70 – -1.70
+13.9% YoY
|
-0.87
-1.52 – -0.49
+62.0% YoY
|
-0.62
-0.81 – -0.28
+29.1% YoY
|
-0.05
-0.06 – -0.05
+91.4% YoY
|
0.68
0.62 – 0.73
+1,368.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-109.49M
OE per share TTM
-1.86
Owner's Yield
-24.75%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
5.5%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
36
Total invested
24.93M
Insider transactions (90d)
1
Beneficial owners (>5%)
20
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 6.76M | 11.80% | 6.39M | — | — | 6.39M | HC | Delaware | 2023-10-06 | ↗ |
| 2 | Consonance Capman GP LLC | 4.66M | 8.88% | — | 4.66M | — | — | HC, OO | Delaware USA | 2019-02-14 | ↗ |
| 3 | Mitchell Blutt | 4.66M | 8.88% | — | 4.66M | — | — | HC, IN | Delaware USA | 2019-02-14 | ↗ |
| 4 | Consonance Capital Management LP | 4.48M | 8.53% | — | 4.48M | — | — | IA, PN | Delaware USA | 2019-02-14 | ↗ |
| 5 | The Vanguard Group - 23-1945930 | 4.46M | 8.36% | 111.2K | 3.6K | 4.35M | 107.1K | IA | Pennsylvania | 2020-02-12 | ↗ |
| 6 | Palo Alto Investors, LLC | 4.16M | 9.25% | — | 4.16M | — | 4.16M | IA, OO | California | 2018-02-14 | ↗ |
| 7 | STATE STREET CORPORATION | 3.33M | 5.97% | — | 3.22M | — | 3.33M | HC | — | 2022-02-14 | ↗ |
| 8 | Armistice Capital Master Fund Ltd. | 3.27M | 6.20% | — | 3.27M | — | 3.27M | CO | Delaware | 2019-06-24 | ↗ |
| 9 | 13-3127734 | 3.21M | 5.77% | 3.21M | — | 3.21M | — | HC | Delaware | 2022-02-11 | ↗ |
| 10 | 26-0385758 | 3.21M | 5.77% | 3.21M | — | 3.21M | — | IA | Delaware | 2022-02-11 | ↗ |
| 11 | Palo Alto Healthcare Master Fund II, L.P. | 2.91M | 5.45% | — | 2.91M | — | 2.91M | PN | Cayman Islands | 2020-02-14 | ↗ |
| 12 | 30-0447847 | 2.85M | 5.00% | 2.78M | — | 2.85M | — | IA | Delaware Limited Partnership | 2023-02-10 | ↗ |
| 13 | Anthony Joonkyoo Yun, MD | 2.83M | 5.09% | — | 2.83M | — | 2.83M | HC, IN | USA | 2022-02-14 | ↗ |
| 14 | PAI LLC | 2.83M | 5.09% | — | 2.83M | — | 2.83M | IA, OO | California | 2022-02-14 | ↗ |
| 15 | Palo Alto Investors LP | 2.83M | 5.09% | — | 2.83M | — | 2.83M | IA, OO | California | 2022-02-14 | ↗ |
| 16 | Patrick Lee, MD | 2.83M | 5.09% | — | 2.83M | — | 2.83M | HC, IN | USA | 2022-02-14 | ↗ |
| 17 | Consonance Capital Opportunity Fund Management LP | 182.9K | 0.35% | — | 182.9K | — | — | IA, PN | Delaware USA | 2019-02-14 | ↗ |
| 18 | Armistice Capital, LLC | — | 0.00% | — | — | — | — | IA, OO | Delaware | 2022-02-15 | ↗ |
| 19 | Deerfield Mgmt, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2018-02-14 | ↗ |
| 20 | Steven Boyd | — | 0.00% | — | — | — | — | HC, IN | Delaware | 2022-02-15 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
36
-125 vs prev Q
New positions
8
Closed positions
126
Increased
19
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 7.77M -1.1M (-12.8%) | 68.56M +24.1M (+54.1%) | 13.15% -1.964 pp | 0.00% +0.000 pp | USD4.70 +87.7% | 6 qtrs — |
| 2 | VANGUARD GROUP INC | 3.73M +144.7K (+4.0%) | 32.91M +15.0M (+83.9%) | 6.31% +0.234 pp | 0.00% +0.000 pp | USD15.07 -41.5% | 77 qtrs — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 3.38M -96.0K (-2.8%) | 29.82M +12.5M (+71.9%) | 5.72% -0.173 pp | 0.05% +0.023 pp | USD11.78 -25.1% | 41 qtrs — |
| 4 | ACADIAN ASSET MANAGEMENT LLC | 2.41M +181.7K (+8.2%) | 21.25M +10.1M (+91.2%) | 4.09% +0.312 pp | 0.03% +0.016 pp | USD6.30 +40.0% | 31 qtrs — |
| 5 | DIMENSIONAL FUND ADVISORS LP | 2.12M -445.5K (-17.4%) | 18.68M +5.9M (+46.0%) | 3.59% -0.751 pp | 0.00% +0.001 pp | USD11.37 -22.4% | 30 qtrs — |
| 6 | AIGH CAPITAL MANAGEMENT LLC | 2.00M +2.0M (+100.0%) | 17.63M +17.6M (+100.0%) | 3.39% +3.395 pp | 4.27% +4.266 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 7 | MILLENNIUM MANAGEMENT LLC | 1.68M -1.6M (-48.4%) | 14.81M -1.4M (-8.7%) | 2.84% -2.669 pp | 0.01% -0.001 pp | USD4.68 +88.5% | 67 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.39M -295.0 (0.0%) | 12.28M +5.3M (+76.7%) | 2.36% -0.005 pp | 0.00% +0.000 pp | USD10.51 -16.1% | 78 qtrs — |
| 9 | STATE STREET CORP | 1.26M -7.5K (-0.6%) | 11.14M +4.8M (+75.7%) | 2.14% -0.017 pp | 0.00% +0.000 pp | USD12.17 -27.5% | 51 qtrs — |
| 10 | KRENSAVAGE ASSET MANAGEMENT, LLC | 1.18M +— (+0.0%) | 10.41M +4.5M (+76.8%) | 2.00% -0.004 pp | 3.68% +1.168 pp | USD4.99 +76.8% | 7 qtrs — |
| 11 | EMPIRE FINANCIAL MANAGEMENT COMPANY, LLC | 1.11M +350.2K (+46.2%) | 9.77M +6.0M (+158.4%) | 1.88% +0.596 pp | 2.12% +1.258 pp | USD6.15 +43.4% | 5 qtrs — |
| 12 | TWO SIGMA ADVISERS, LP | 1.05M +140.0K (+15.4%) | 9.25M +4.7M (+104.0%) | 1.78% +0.234 pp | 0.02% +0.009 pp | USD6.08 +45.1% | 39 qtrs — |
| 13 | TWO SIGMA INVESTMENTS, LP | 979.0K +316.7K (+47.8%) | 8.63M +5.3M (+161.3%) | 1.66% +0.534 pp | 0.01% +0.007 pp | USD6.45 +36.7% | 39 qtrs — |
| 14 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 743.5K -161.0K (-17.8%) | 6.56M +2.0M (+45.3%) | 1.26% -0.272 pp | 0.02% +0.003 pp | USD5.55 +58.9% | 15 qtrs — |
| 15 | JACOBS LEVY EQUITY MANAGEMENT, INC | 708.4K +599.8K (+552.3%) | 6.25M +5.7M (+1,052.9%) | 1.20% +1.018 pp | 0.02% +0.022 pp | USD8.66 +1.8% | 22 qtrs — |
| 16 | AQR CAPITAL MANAGEMENT LLC | 627.0K -41.5K (-6.2%) | 5.53M +2.2M (+65.8%) | 1.06% -0.069 pp | 0.00% +0.001 pp | USD4.96 +77.8% | 9 qtrs — |
| 17 | MORGAN STANLEY | 593.0K -44.5K (-7.0%) | 5.23M +2.0M (+64.4%) | 1.00% -0.077 pp | 0.00% +0.000 pp | USD5.56 +58.6% | 51 qtrs — |
| 18 | FEDERATED HERMES, INC. | 554.4K -127.4K (-18.7%) | 4.89M +1.5M (+43.7%) | 0.94% -0.215 pp | 0.01% +0.002 pp | USD9.56 -7.7% | 30 qtrs — |
| 19 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 500.5K +11.6K (+2.4%) | 4.41M +2.0M (+80.9%) | 0.85% +0.021 pp | 0.00% +0.000 pp | USD13.78 -36.0% | 57 qtrs — |
| 20 | JUMP FINANCIAL, LLC | 473.8K +335.8K (+243.3%) | 4.18M +3.5M (+506.9%) | 0.80% +0.570 pp | 0.05% +0.043 pp | USD7.70 +14.5% | 2 qtrs — |
| 21 | NORTHERN TRUST CORP | 429.1K -25.5K (-5.6%) | 3.78M +1.5M (+66.9%) | 0.73% -0.042 pp | 0.00% +0.000 pp | USD14.09 -37.4% | 51 qtrs — |
| 22 | GOLDMAN SACHS GROUP INC | 408.3K +68.6K (+20.2%) | 3.60M +1.9M (+112.5%) | 0.69% +0.115 pp | 0.00% +0.000 pp | USD8.21 +7.4% | 51 qtrs — |
| 23 | JPMORGAN CHASE & CO | 396.0K +196.1K (+98.1%) | 3.49M +2.5M (+250.2%) | 0.67% +0.334 pp | 0.00% +0.000 pp | USD7.23 +22.0% | 41 qtrs — |
| 24 | CAPTION MANAGEMENT, LLC | 349.3K +312.3K (+844.1%) | 3.08M +2.9M (+1,568.6%) | 0.59% +0.528 pp | 0.02% +0.020 pp | USD8.41 +4.9% | 2 qtrs — |
| 25 | NUVEEN, LLC | 291.5K +120.4K (+70.4%) | 2.57M +1.7M (+201.2%) | 0.49% +0.203 pp | 0.00% +0.000 pp | USD6.40 +37.8% | 4 qtrs — |
| 26 | QUANTINNO CAPITAL MANAGEMENT LP | 261.8K +179.5K (+218.1%) | 2.31M +1.9M (+462.3%) | 0.44% +0.305 pp | 0.00% +0.004 pp | USD7.59 +16.2% | 5 qtrs — |
| 27 | KENNEDY CAPITAL MANAGEMENT LLC | 235.2K -1.5K (-0.6%) | 2.07M +893.3K (+75.7%) | 0.40% -0.002 pp | 0.04% +0.018 pp | USD5.52 +59.8% | 7 qtrs — |
| 28 | FMR LLC | 222.3K +42.7K (+23.8%) | 1.96M +1.1M (+118.8%) | 0.38% +0.073 pp | 0.00% +0.000 pp | USD7.06 +24.9% | 20 qtrs — |
| 29 | TREXQUANT INVESTMENT LP | 204.5K +204.5K (+100.0%) | 1.80M +1.8M (+100.0%) | 0.35% +0.346 pp | 0.02% +0.016 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 30 | DIADEMA PARTNERS LP | 200.0K +200.0K (+100.0%) | 1.76M +1.8M (+100.0%) | 0.34% +0.338 pp | 0.30% +0.304 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 31 | MONACO ASSET MANAGEMENT SAM | 196.3K -51.5K (-20.8%) | 1.73M +494.7K (+40.0%) | 0.33% -0.087 pp | 0.30% +0.225 pp | USD5.18 +70.3% | 10 qtrs — |
| 32 | BARCLAYS PLC | 191.0K +36.7K (+23.8%) | 1.68M +961.3K (+132.8%) | 0.32% +0.062 pp | 0.00% +0.000 pp | USD6.36 +38.7% | 51 qtrs — |
| 33 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 190.6K +60.7K (+46.7%) | 1.68M +1.0M (+159.3%) | 0.32% +0.102 pp | 0.00% +0.000 pp | USD6.03 +46.3% | 28 qtrs — |
| 34 | SEI INVESTMENTS CO | 190.3K +— (+0.0%) | 1.68M +728.7K (+76.8%) | 0.32% +0.000 pp | 0.00% +0.001 pp | USD6.77 +30.3% | 37 qtrs — |
| 35 | WELLINGTON MANAGEMENT GROUP LLP | 178.9K -10.2K (-5.4%) | 1.58M +634.1K (+67.2%) | 0.30% -0.017 pp | 0.00% +0.000 pp | USD4.24 +108.0% | 11 qtrs — |
| 36 | JANNEY MONTGOMERY SCOTT LLC | 175.5K +175.5K (+100.0%) | 1.55M +1.5M (+100.0%) | 0.30% +0.298 pp | 0.00% +0.004 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 37 | BANK OF NEW YORK MELLON CORP | 171.7K -7.9K (-4.4%) | 1.51M +617.8K (+68.9%) | 0.29% -0.013 pp | 0.00% +0.000 pp | USD15.55 -43.3% | 66 qtrs — |
| 38 | CITADEL ADVISORS LLC | 156.4K +136.7K (+693.9%) | 1.38M +1.3M (+1,303.3%) | 0.26% +0.231 pp | 0.00% +0.000 pp | USD8.30 +6.3% | 22 qtrs — |
| 39 | CITIGROUP INC | 152.5K +125.9K (+473.1%) | 1.34M +1.2M (+913.0%) | 0.26% +0.214 pp | 0.00% +0.001 pp | USD8.10 +8.9% | 56 qtrs — |
| 40 | STATE OF WISCONSIN INVESTMENT BOARD | 150.5K +48.1K (+47.0%) | 1.33M +816.8K (+159.9%) | 0.26% +0.082 pp | 0.00% +0.002 pp | USD6.31 +39.8% | 35 qtrs — |
| 41 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 150.4K +39.1K (+35.1%) | 1.33M +771.2K (+138.8%) | 0.25% +0.066 pp | 0.02% +0.012 pp | USD5.81 +51.8% | 3 qtrs — |
| 42 | AMERICAN CENTURY COMPANIES INC | 150.4K +4.2K (+2.8%) | 1.33M +596.8K (+81.8%) | 0.26% +0.007 pp | 0.00% +0.000 pp | USD5.32 +65.8% | 31 qtrs — |
| 43 | GSA CAPITAL PARTNERS LLP | 148.8K -170.0K (-53.3%) | 1.31M -279.0K (-17.5%) | 0.25% -0.288 pp | 0.11% -0.020 pp | USD4.70 +87.7% | 17 qtrs — |
| 44 | SQUAREPOINT OPS LLC | 135.8K +21.3K (+18.6%) | 1.20M +626.5K (+109.6%) | 0.23% +0.036 pp | 0.00% +0.001 pp | USD5.36 +64.6% | 13 qtrs — |
| 45 | KLP KAPITALFORVALTNING AS | 135.4K +— (+0.0%) | 1.19M +518.6K (+76.8%) | 0.23% +0.001 pp | 0.00% +0.002 pp | USD4.79 +84.1% | 5 qtrs — |
| 46 | UBS GROUP AG | 124.7K -1.5K (-1.2%) | 1.10M +470.2K (+74.7%) | 0.21% -0.003 pp | 0.00% +0.000 pp | USD5.65 +56.1% | 45 qtrs — |
| 47 | INVESCO LTD. | 123.0K -18.3K (-12.9%) | 1.08M +380.0K (+53.9%) | 0.21% -0.031 pp | 0.00% +0.000 pp | USD7.53 +17.1% | 57 qtrs — |
| 48 | PANAGORA ASSET MANAGEMENT INC | 119.0K +3.9K (+3.4%) | 1.05M +475.3K (+82.8%) | 0.20% +0.007 pp | 0.00% +0.001 pp | USD5.12 +72.3% | 2 qtrs — |
| 49 | AMERIPRISE FINANCIAL INC | 112.4K +82.9K (+281.1%) | 991.3K +844.2K (+573.6%) | 0.19% +0.141 pp | 0.00% +0.000 pp | USD10.32 -14.5% | 35 qtrs — |
| 50 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 103.4K -35.4K (-25.5%) | 912.4K +219.8K (+31.7%) | 0.18% -0.060 pp | 0.00% +0.000 pp | USD4.69 +88.1% | 22 qtrs — |
| 51 | KOTLER KEVIN | 100.0K +100.0K (+100.0%) | 882.0K +882.0K (+100.0%) | 0.17% +0.169 pp | 0.21% +0.206 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 52 | SIMPLEX TRADING, LLC | 94.1K +62.4K (+197.1%) | 830.1K +672.1K (+425.4%) | 0.16% +0.106 pp | 0.00% +0.000 pp | USD7.44 +18.5% | 12 qtrs — |
| 53 | ALLIANCEBERNSTEIN L.P. | 91.4K -12.8K (-12.3%) | 806.4K +286.2K (+55.0%) | 0.15% -0.022 pp | 0.00% +0.000 pp | USD9.52 -7.4% | 61 qtrs — |
| 54 | TUDOR INVESTMENT CORP ET AL | 88.6K -40.0K (-31.1%) | 781.3K +139.5K (+21.7%) | 0.15% -0.068 pp | 0.00% +0.000 pp | USD4.62 +90.9% | 9 qtrs — |
| 55 | JANE STREET GROUP, LLC | 84.8K +84.8K (+100.0%) | 747.9K +747.9K (+100.0%) | 0.14% +0.144 pp | 0.00% +0.000 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 56 | BANK OF AMERICA CORP /DE/ | 81.4K -25.0K (-23.5%) | 718.1K +187.0K (+35.2%) | 0.14% -0.043 pp | 0.00% +0.000 pp | USD4.48 +96.9% | 52 qtrs — |
| 57 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 79.6K -46.1K (-36.7%) | 702.1K +74.8K (+11.9%) | 0.13% -0.078 pp | 0.01% +0.001 pp | USD6.13 +43.9% | 13 qtrs — |
| 58 | RHUMBLINE ADVISERS | 73.2K -12.0K (-14.1%) | 646.0K +220.4K (+51.8%) | 0.12% -0.021 pp | 0.00% +0.000 pp | USD15.07 -41.5% | 52 qtrs — |
| 59 | WELLS FARGO & COMPANY/MN | 68.7K +19.7K (+40.3%) | 606.3K +361.8K (+148.0%) | 0.12% +0.033 pp | 0.00% +0.000 pp | USD6.47 +36.3% | 57 qtrs — |
| 60 | BALYASNY ASSET MANAGEMENT L.P. | 68.2K +68.2K (+100.0%) | 601.3K +601.3K (+100.0%) | 0.12% +0.116 pp | 0.00% +0.001 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 61 | INSCRIPTION CAPITAL, LLC | 63.9K +47.6K (+293.5%) | 563.4K +482.4K (+595.6%) | 0.11% +0.081 pp | 0.06% +0.049 pp | USD7.85 +12.4% | 2 qtrs — |
| 62 | RUSSELL INVESTMENTS GROUP, LTD. | 62.3K +55.8K (+858.5%) | 549.1K +516.7K (+1,594.2%) | 0.11% +0.095 pp | 0.00% +0.001 pp | USD8.45 +4.4% | 37 qtrs — |
| 63 | POINT72 ASSET MANAGEMENT, L.P. | 61.5K +61.5K (+100.0%) | 542.1K +542.1K (+100.0%) | 0.10% +0.104 pp | 0.00% +0.001 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 64 | SCHONFELD STRATEGIC ADVISORS LLC | 59.1K +59.1K (+100.0%) | 521.3K +521.3K (+100.0%) | 0.10% +0.100 pp | 0.00% +0.002 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 65 | STEMPOINT CAPITAL LP | 59.0K +59.0K (+100.0%) | 520.3K +520.3K (+100.0%) | 0.10% +0.100 pp | 0.09% +0.089 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 66 | GROUP ONE TRADING, L.P. | 54.3K +46.6K (+598.5%) | 479.3K +440.5K (+1,134.6%) | 0.09% +0.079 pp | 0.00% +0.001 pp | USD8.27 +6.7% | 12 qtrs — |
| 67 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 53.1K +53.1K (+100.0%) | 468.0K +468.0K (+100.0%) | 0.09% +0.090 pp | 0.01% +0.005 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 68 | DEUTSCHE BANK AG\ | 50.3K -352.0 (-0.7%) | 443.5K +190.8K (+75.5%) | 0.09% 0.000 pp | 0.00% +0.000 pp | USD4.99 +76.8% | 50 qtrs — |
| 69 | FULLER & THALER ASSET MANAGEMENT, INC. | 49.8K +— (+0.0%) | 438.8K +190.5K (+76.8%) | 0.08% 0.000 pp | 0.00% +0.001 pp | USD4.69 +88.1% | 6 qtrs — |
| 70 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 48.8K +27.5K (+129.8%) | 430.1K +324.2K (+306.2%) | 0.08% +0.047 pp | 0.00% +0.001 pp | USD8.42 +4.8% | 16 qtrs — |
| 71 | ALPS ADVISORS INC | 48.5K +20.6K (+73.8%) | 428.0K +288.6K (+207.1%) | 0.08% +0.035 pp | 0.00% +0.002 pp | USD9.42 -6.4% | 22 qtrs — |
| 72 | MERCER GLOBAL ADVISORS INC /ADV | 43.8K +14.8K (+51.2%) | 386.6K +241.9K (+167.2%) | 0.07% +0.025 pp | 0.00% +0.000 pp | USD6.29 +40.2% | 2 qtrs — |
| 73 | BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC | 39.4K +— (+0.0%) | 347.4K +150.9K (+76.8%) | 0.07% +0.000 pp | 0.00% +0.001 pp | USD4.70 +87.7% | 6 qtrs — |
| 74 | HSBC HOLDINGS PLC | 35.7K -35.5K (-49.9%) | 320.9K -33.2K (-9.4%) | 0.06% -0.060 pp | 0.00% +0.000 pp | USD4.73 +86.5% | 6 qtrs — |
| 75 | PRICE T ROWE ASSOCIATES INC /MD/ | 35.3K +6.0K (+20.6%) | 312.0K +166.0K (+113.7%) | 0.06% +0.010 pp | 0.00% +0.000 pp | USD6.05 +45.8% | 12 qtrs — |
| 76 | MARTINGALE ASSET MANAGEMENT L P | 33.1K +15.4K (+87.3%) | 292.1K +203.8K (+231.0%) | 0.06% +0.026 pp | 0.01% +0.005 pp | USD8.67 +1.7% | 23 qtrs — |
| 77 | IEQ CAPITAL, LLC | 31.1K -20.8K (-40.1%) | 274.0K +15.2K (+5.9%) | 0.05% -0.035 pp | 0.00% +0.000 pp | USD4.93 +78.9% | 3 qtrs — |
| 78 | CERITY PARTNERS LLC | 30.3K -807.0 (-2.6%) | 267.2K +112.0K (+72.2%) | 0.05% -0.001 pp | 0.00% +0.000 pp | USD4.86 +81.5% | 3 qtrs — |
| 79 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 29.2K +28.8K (+8,629.9%) | 257.2K +255.5K (+15,327.4%) | 0.05% +0.049 pp | 0.06% +0.061 pp | USD8.77 +0.6% | 3 qtrs — |
| 80 | CWM, LLC | 27.0K -6.2K (-18.6%) | 238.0K +73.0K (+44.2%) | 0.05% -0.011 pp | 0.00% +0.000 pp | USD4.94 +78.5% | 17 qtrs — |
| 81 | AXQ CAPITAL, LP | 26.6K +26.6K (+100.0%) | 234.2K +234.2K (+100.0%) | 0.05% +0.045 pp | 0.05% +0.053 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 82 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 25.8K -306.0 (-1.2%) | 227.8K +97.4K (+74.7%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD5.45 +61.8% | 7 qtrs — |
| 83 | HORIZON KINETICS ASSET MANAGEMENT LLC | 24.8K -1.1K (-4.2%) | 218.9K +89.6K (+69.3%) | 0.04% -0.002 pp | 0.00% +0.001 pp | USD6.63 +33.0% | 12 qtrs — |
| 84 | METLIFE INVESTMENT MANAGEMENT, LLC | 24.4K -7.9K (-24.4%) | 215.3K +54.1K (+33.5%) | 0.04% -0.013 pp | 0.00% +0.000 pp | USD11.93 -26.1% | 33 qtrs — |
| 85 | INTECH INVESTMENT MANAGEMENT LLC | 23.3K -2.6K (-10.0%) | 205.1K +76.2K (+59.1%) | 0.04% -0.004 pp | 0.00% +0.001 pp | USD4.70 +87.7% | 6 qtrs — |
| 86 | STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | 23.1K +— (+0.0%) | 203.7K +88.5K (+76.8%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD7.01 +25.8% | 51 qtrs — |
| 87 | CANADA PENSION PLAN INVESTMENT BOARD | 23.1K +23.1K (+100.0%) | 203.7K +203.7K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 88 | GRAHAM CAPITAL MANAGEMENT, L.P. | 23.1K +23.1K (+100.0%) | 203.4K +203.4K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.005 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 89 | WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 23.4K +5.9K (+33.8%) | 190.3K +97.3K (+104.6%) | 0.04% +0.010 pp | 0.00% +0.000 pp | USD5.96 +48.0% | 2 qtrs — |
| 90 | QUBE RESEARCH & TECHNOLOGIES LTD | 20.7K -158.6K (-88.5%) | 182.2K -712.3K (-79.6%) | 0.04% -0.269 pp | 0.00% -0.001 pp | USD4.99 +76.8% | 5 qtrs — |
| 91 | D. E. SHAW & CO., INC. | 18.6K -103.7K (-84.8%) | 164.1K -446.4K (-73.1%) | 0.03% -0.176 pp | 0.00% 0.000 pp | USD8.39 +5.1% | 49 qtrs — |
| 92 | ROBERTSON STEPHENS WEALTH MANAGEMENT, LLC | 18.0K +18.0K (+100.0%) | 158.8K +158.8K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.004 pp | USD8.82 +0.0% | 1 qtrs NEW |
| 93 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 17.5K -1.6K (-8.2%) | 154.3K +59.2K (+62.3%) | 0.03% -0.003 pp | 0.00% +0.000 pp | USD15.91 -44.6% | 51 qtrs — |
| 94 | MARINER, LLC | 16.8K -566.0 (-3.3%) | 146.2K +59.4K (+68.4%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD4.99 +76.8% | 2 qtrs — |
| 95 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 20.0K -160.0K (-88.9%) | 140.6K -757.6K (-84.3%) | 0.03% -0.271 pp | 0.00% -0.001 pp | USD4.59 +92.2% | 4 qtrs — |
| 96 | BNP PARIBAS ARBITRAGE, SNC | 15.9K -49.6K (-75.8%) | 140.2K -186.9K (-57.1%) | 0.03% -0.084 pp | 0.00% 0.000 pp | USD4.96 +77.8% | 46 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 90 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Horizon Kinetics Medical ETF MEDX | 0.76% | 141.3K | 0.85% |
| 2 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.48% | 106.1K | 0.20% |
| 3 | Harbor Human Capital Factor US Small Cap ETF HAPS | 0.19% | 321.0K | 0.61% |
| 4 | Federated Hermes MDT Small Cap Core ETF FSCC | 0.16% | 258.8K | 0.51% |
| 5 | Royce Quant Small-Cap Quality Value ETF SQLV | 0.15% | 42.5K | 0.60% |
| 6 | State Street SPDR S&P Biotech ETF XBI | 0.13% | 14.34M | 0.35% |
| 7 | Global X - S&P Biotech ETF CURE.AX | 0.13% | 46.2K | 0.45% |
| 8 | Vanguard U.S. Momentum Factor ETF VFMO | 0.10% | 1.76M | 0.13% |
| 9 | Vanguard U.S. Multifactor ETF VFMF | 0.09% | 562.2K | 0.18% |
| 10 | iShares Micro-Cap ETF IWC | 0.08% | 1.13M | 0.60% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
57.1K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+57,101
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | Duncan Charles Cliff | Director | A-Award | A | Common Stock | 57,101 | 0.00 | — | 57,101 | D | ↗ |
| 2026-04-01 | Polymeropoulos Christos Vasilios Mihael | Director / Officer | — | — | Stock Option (Right to Buy) | 61,200 | 7.05 | 431.5K | 0 | D | ↗ |
| 2026-04-01 | Howell Scott Laverne | Officer | — | — | Common Stock | 0 | 0.00 | — | 75,000 | D | ↗ |
| 2026-03-02 | Williams Timothy | Officer | S-Sale | D | Common Stock | 42,434 | 8.27 | 350.8K | 377,450 | D | ↗ |
| 2026-03-02 | Wijkstrom Joakim | Officer | S-Sale | D | Common Stock | 30,800 | 8.27 | 254.6K | 333,469 | D | ↗ |
| 2026-03-02 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 156,235 | 8.17 | 1.28M | 2,704,496 | D | ↗ |
| 2026-03-02 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 42,442 | 8.27 | 350.8K | 411,380 | D | ↗ |
| 2026-03-02 | Birznieks Gunther | Officer | S-Sale | D | Common Stock | 42,431 | 8.27 | 350.7K | 494,197 | D | ↗ |
| 2026-02-23 | Honore Tage | Director | S-Sale | D | Common Stock | 30,000 | 8.03 | 240.9K | 93,469 | D | ↗ |
| 2026-02-18 | Williams Timothy | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 419,884 | D | ↗ |
| 2026-02-18 | Wijkstrom Joakim | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 364,269 | D | ↗ |
| 2026-02-18 | Polymeropoulos Mihael Hristos | Director / Officer | A-Award | A | Common Stock | 525,000 | 0.00 | — | 2,860,731 | D | ↗ |
| 2026-02-18 | Moran Kevin Patrick | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 453,822 | D | ↗ |
| 2026-02-18 | Birznieks Gunther | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 536,628 | D | ↗ |
| 2025-08-07 | Polymeropoulos Mihael Hristos | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 4.15 | 41.5K | 2,335,731 | D | ↗ |
| 2025-06-13 | Mitchell Stephen Ray | Director | S-Sale | D | Common Stock | 7,000 | 4.59 | 32.1K | 97,082 | D | ↗ |
| 2025-06-05 | Ward Anne Sempowski | Director | A-Award | A | Common Stock | 59,225 | 0.00 | — | 119,067 | D | ↗ |
| 2025-06-05 | Mitchell Stephen Ray | Director | A-Award | A | Common Stock | 59,225 | 0.00 | — | 104,082 | D | ↗ |
| 2025-06-05 | Honore Tage | Director | A-Award | A | Common Stock | 59,225 | 0.00 | — | 123,469 | D | ↗ |
| 2025-06-05 | DUGAN RICHARD W | Director | A-Award | A | Common Stock | 59,225 | 0.00 | — | 177,454 | D | ↗ |
| 2025-06-05 | Chrousos Phaedra | Director | A-Award | A | Common Stock | 59,225 | 0.00 | — | 123,350 | D | ↗ |
| 2025-05-21 | Polymeropoulos Mihael Hristos | Director / Officer | P-Purchase | A | Common Stock | 9,519 | 4.40 | 41.9K | 2,325,250 | D | ↗ |
| 2025-05-16 | Polymeropoulos Mihael Hristos | Director / Officer | P-Purchase | A | Common Stock | 20,000 | 4.22 | 84.5K | 2,315,731 | D | ↗ |
| 2025-03-06 | Polymeropoulos Mihael Hristos | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 5.02 | 25.1K | 2,290,731 | D | ↗ |
| 2025-03-05 | Polymeropoulos Mihael Hristos | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 5.03 | 25.2K | 2,285,731 | D | ↗ |
| 2025-03-03 | Polymeropoulos Mihael Hristos | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 4.71 | 47.1K | 2,275,731 | D | ↗ |
| 2025-03-01 | Williams Timothy | Officer | F-InKind | D | Common Stock | 26,941 | 4.76 | 128.2K | 294,884 | D | ↗ |
| 2025-03-01 | Wijkstrom Joakim | Officer | F-InKind | D | Common Stock | 15,520 | 4.76 | 73.9K | 239,269 | D | ↗ |
| 2025-03-01 | Polymeropoulos Mihael Hristos | Director / Officer | F-InKind | D | Common Stock | 95,999 | 4.76 | 457.0K | 2,265,731 | D | ↗ |
| 2025-03-01 | Moran Kevin Patrick | Officer | F-InKind | D | Common Stock | 26,941 | 4.76 | 128.2K | 328,822 | D | ↗ |
| 2025-03-01 | Birznieks Gunther | Officer | F-InKind | D | Common Stock | 26,941 | 4.76 | 128.2K | 411,628 | D | ↗ |
| 2025-02-28 | Polymeropoulos Mihael Hristos | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 4.76 | 47.6K | 2,361,730 | D | ↗ |
| 2025-02-27 | Polymeropoulos Mihael Hristos | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 4.76 | 47.6K | 2,351,730 | D | ↗ |
| 2025-02-26 | Polymeropoulos Mihael Hristos | Director / Officer | P-Purchase | A | Common Stock | 5,000 | 4.78 | 23.9K | 2,341,730 | D | ↗ |
| 2025-02-25 | Polymeropoulos Mihael Hristos | Director / Officer | P-Purchase | A | Common Stock | 10,000 | 4.46 | 44.6K | 2,331,730 | D | ↗ |
| 2025-02-21 | Moran Kevin Patrick | Officer | P-Purchase | A | Common Stock | 2,000 | 4.39 | 8.8K | 355,763 | D | ↗ |
| 2025-02-18 | Williams Timothy | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 321,825 | D | ↗ |
| 2025-02-18 | Wijkstrom Joakim | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 254,789 | D | ↗ |
| 2025-02-18 | Polymeropoulos Mihael Hristos | Director / Officer | A-Award | A | Common Stock | 450,000 | 0.00 | — | 2,321,730 | D | ↗ |
| 2025-02-18 | Moran Kevin Patrick | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 353,763 | D | ↗ |
| 2025-02-18 | Birznieks Gunther | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 438,569 | D | ↗ |
| 2024-11-14 | Mitchell Stephen Ray | Director | S-Sale | D | Common Stock | 5,000 | 5.17 | 25.9K | 44,857 | D | ↗ |
| 2024-07-29 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 2,251 | 5.92 | 13.3K | 228,763 | — | ↗ |
| 2024-05-22 | Chrousos Phaedra | Director | A-Award | A | Common Stock | 21,887 | 0.00 | — | 64,125 | — | ↗ |
| 2024-05-17 | Ward Anne Sempowski | Director | A-Award | A | Common Stock | 20,529 | 0.00 | — | 59,842 | — | ↗ |
| 2024-05-17 | Mitchell Stephen Ray | Director | A-Award | A | Common Stock | 20,529 | 0.00 | — | 49,857 | — | ↗ |
| 2024-05-17 | Honore Tage | Director | A-Award | A | Common Stock | 20,529 | 0.00 | — | 64,244 | — | ↗ |
| 2024-05-17 | DUGAN RICHARD W | Director | A-Award | A | Common Stock | 20,529 | 0.00 | — | 118,229 | — | ↗ |
| 2024-03-05 | Williams Timothy | Officer | S-Sale | D | Common Stock | 8,941 | 4.18 | 37.4K | 196,825 | — | ↗ |
| 2024-03-05 | Wijkstrom Joakim | Officer | S-Sale | D | Common Stock | 9,229 | 4.21 | 38.8K | 129,789 | — | ↗ |
| 2024-03-05 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 24,288 | 4.13 | 100.3K | 1,871,730 | — | ↗ |
| 2024-03-05 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 8,902 | 4.20 | 37.4K | 231,014 | — | ↗ |
| 2024-03-05 | Birznieks Gunther | Officer | S-Sale | D | Common Stock | 8,684 | 4.13 | 35.9K | 313,569 | — | ↗ |
| 2024-03-04 | Williams Timothy | Officer | S-Sale | D | Common Stock | 8,147 | 4.41 | 35.9K | 205,766 | — | ↗ |
| 2024-03-04 | Wijkstrom Joakim | Officer | S-Sale | D | Common Stock | 7,498 | 4.41 | 33.1K | 139,018 | — | ↗ |
| 2024-03-04 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 30,884 | 4.24 | 131.1K | 1,896,018 | — | ↗ |
| 2024-03-04 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 5,798 | 4.48 | 26.0K | 239,916 | — | ↗ |
| 2024-03-04 | Birznieks Gunther | Officer | S-Sale | D | Common Stock | 8,727 | 4.30 | 37.5K | 322,253 | — | ↗ |
| 2024-02-16 | Williams Timothy | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 213,913 | — | ↗ |
| 2024-02-16 | Wijkstrom Joakim | Officer | A-Award | A | Common Stock | 32,700 | 0.00 | — | 146,516 | — | ↗ |
| 2024-02-16 | Polymeropoulos Mihael Hristos | Director / Officer | A-Award | A | Common Stock | 450,000 | 0.00 | — | 1,926,902 | — | ↗ |
| 2024-02-16 | Moran Kevin Patrick | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 245,714 | — | ↗ |
| 2024-02-16 | Birznieks Gunther | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 330,980 | — | ↗ |
| 2023-08-21 | Wijkstrom Joakim | Officer | S-Sale | D | Common Stock | 3,724 | 5.84 | 21.7K | 113,816 | — | ↗ |
| 2023-08-10 | Mitchell Stephen Ray | Director | S-Sale | D | Common Stock | 6,500 | 6.05 | 39.3K | 29,328 | — | ↗ |
| 2023-07-28 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 412 | 6.30 | 2.6K | 122,514 | — | ↗ |
| 2023-06-15 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 16,000 | 6.29 | 100.7K | 122,926 | — | ↗ |
| 2023-06-13 | Williams Timothy | Officer | S-Sale | D | Common Stock | 14,600 | 6.56 | 95.8K | 88,913 | — | ↗ |
| 2023-06-08 | Ward Anne Sempowski | Director | A-Award | A | Stock Option (right to buy) | 33,960 | 6.50 | 220.7K | 33,960 | — | ↗ |
| 2023-06-08 | Mitchell Stephen Ray | Director | A-Award | A | Stock Option (right to buy) | 33,960 | 6.50 | 220.7K | 33,960 | — | ↗ |
| 2023-06-08 | Honore Tage | Director | A-Award | A | Common Stock | 17,307 | 0.00 | — | 43,715 | — | ↗ |
| 2023-06-08 | DUGAN RICHARD W | Director | A-Award | A | Stock Option (Right to Buy) | 33,960 | 6.50 | 220.7K | 33,960 | — | ↗ |
| 2023-06-08 | Chrousos Phaedra | Director | A-Award | A | Stock Option (Right to Buy) | 33,960 | 6.50 | 220.7K | 33,960 | — | ↗ |
| 2023-03-15 | Honore Tage | Director | A-Award | A | Stock Option (right to buy) | 51,276 | 6.39 | 327.7K | 51,276 | — | ↗ |
| 2023-03-03 | Williams Timothy | Officer | S-Sale | D | Common Stock | 8,301 | 6.25 | 51.9K | 103,513 | — | ↗ |
| 2023-03-03 | Wijkstrom Joakim | Officer | S-Sale | D | Common Stock | 4,113 | 6.32 | 26.0K | 117,540 | — | ↗ |
| 2023-03-03 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 22,538 | 6.25 | 140.9K | 1,476,902 | — | ↗ |
| 2023-03-03 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 5,968 | 6.28 | 37.5K | 138,926 | — | ↗ |
| 2023-03-03 | Birznieks Gunther | Officer | S-Sale | D | Common Stock | 8,268 | 6.26 | 51.8K | 205,980 | — | ↗ |
| 2023-03-02 | Williams Timothy | Officer | S-Sale | D | Common Stock | 8,437 | 6.24 | 52.7K | 111,814 | — | ↗ |
| 2023-03-02 | Wijkstrom Joakim | Officer | S-Sale | D | Common Stock | 7,720 | 6.23 | 48.1K | 121,653 | — | ↗ |
| 2023-03-02 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 22,426 | 6.23 | 139.7K | 1,499,440 | — | ↗ |
| 2023-03-02 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 7,966 | 6.26 | 49.8K | 144,894 | — | ↗ |
| 2023-03-02 | Birznieks Gunther | Officer | S-Sale | D | Common Stock | 8,509 | 6.20 | 52.8K | 214,248 | — | ↗ |
| 2023-02-16 | Williams Timothy | Officer | A-Award | A | Stock Option (Right to Buy) | 77,500 | 7.05 | 546.4K | 77,500 | — | ↗ |
| 2023-02-16 | Wijkstrom Joakim | Officer | A-Award | A | Stock Option (Right to Buy) | 77,500 | 7.05 | 546.4K | 77,500 | — | ↗ |
| 2023-02-16 | Polymeropoulos Mihael Hristos | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 7.05 | 1.94M | 275,000 | — | ↗ |
| 2023-02-16 | Moran Kevin Patrick | Officer | A-Award | A | Stock Option (Right to Buy) | 77,500 | 7.05 | 546.4K | 77,500 | — | ↗ |
| 2023-02-16 | Birznieks Gunther | Officer | A-Award | A | Common Stock | 32,700 | 0.00 | — | 222,757 | — | ↗ |
| 2022-12-15 | Williams Timothy | Officer | S-Sale | D | Common Stock | 8,000 | 7.01 | 56.1K | 87,551 | — | ↗ |
| 2022-12-06 | Polymeropoulos Mihael Hristos | Officer | M-Exempt | D | Stock Option (Right to Buy) | 75,365 | 0.00 | — | 0 | — | ↗ |
| 2022-12-06 | Moran Kevin Patrick | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,500 | 0.00 | — | 0 | — | ↗ |
| 2022-12-05 | Polymeropoulos Mihael Hristos | Officer | S-Sale | D | Common Stock | 47,650 | 10.62 | 506.2K | 1,379,751 | — | ↗ |
| 2022-08-26 | Birznieks Gunther | Officer | M-Exempt | A | Common Stock | 1,250 | 3.12 | 3.9K | 190,057 | — | ↗ |
| 2022-08-22 | Wijkstrom Joakim | Officer | S-Sale | D | Common Stock | 3,605 | 10.27 | 37.0K | 96,673 | — | ↗ |
| 2022-08-15 | Williams Timothy | Officer | S-Sale | D | Common Stock | 3,689 | 10.42 | 38.4K | 100,162 | — | ↗ |
| 2022-07-28 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 2,239 | 10.97 | 24.6K | 117,452 | — | ↗ |
| 2022-06-16 | Ward Anne Sempowski | Director | A-Award | A | Common Stock | 12,006 | 0.00 | — | 22,006 | — | ↗ |
| 2022-06-16 | Mitchell Stephen Ray | Director | A-Award | A | Common Stock | 12,006 | 0.00 | — | 18,521 | — | ↗ |
| 2022-06-16 | DUGAN RICHARD W | Director | A-Award | A | Stock Option (Right to Buy) | 24,707 | 9.37 | 231.5K | 24,707 | — | ↗ |
| 2022-06-16 | Chrousos Phaedra | Director | A-Award | A | Stock Option (Right to Buy) | 24,707 | 9.37 | 231.5K | 24,707 | — | ↗ |
| 2022-06-13 | Mitchell Stephen Ray | Director | S-Sale | D | Common Stock | 2,700 | 9.48 | 25.6K | 6,515 | — | ↗ |
| 2022-06-02 | Watkins Thomas | Director | M-Exempt | A | Common Stock | 15,000 | 4.15 | 62.3K | 69,505 | — | ↗ |
| 2022-05-31 | DUGAN RICHARD W | Director | M-Exempt | A | Common Stock | 15,000 | 4.15 | 62.3K | 74,887 | — | ↗ |
| 2022-03-02 | Williams Timothy | Officer | S-Sale | D | Common Stock | 12,060 | 11.09 | 133.8K | 103,851 | — | ↗ |
| 2022-03-02 | Wijkstrom Joakim | Officer | S-Sale | D | Common Stock | 6,974 | 11.19 | 78.1K | 100,278 | — | ↗ |
| 2022-03-02 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 29,588 | 11.15 | 329.9K | 1,352,766 | — | ↗ |
| 2022-03-02 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 8,832 | 11.28 | 99.6K | 119,691 | — | ↗ |
| 2022-03-02 | Birznieks Gunther | Officer | S-Sale | D | Common Stock | 11,517 | 11.27 | 129.8K | 188,807 | — | ↗ |
| 2022-03-01 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 7,508 | 11.19 | 84.0K | 1,382,354 | — | ↗ |
| 2022-03-01 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 3,473 | 11.19 | 38.9K | 128,523 | — | ↗ |
| 2022-03-01 | Birznieks Gunther | Officer | S-Sale | D | Common Stock | 4,084 | 11.19 | 45.7K | 200,324 | — | ↗ |
| 2022-02-28 | Williams Timothy | Officer | A-Award | A | Common Stock | 32,700 | 0.00 | — | 115,911 | — | ↗ |
| 2022-02-28 | Wijkstrom Joakim | Officer | A-Award | A | Common Stock | 32,700 | 0.00 | — | 107,252 | — | ↗ |
| 2022-02-28 | Polymeropoulos Mihael Hristos | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 275,000 | 11.36 | 3.12M | 275,000 | — | ↗ |
| 2022-02-28 | Moran Kevin Patrick | Officer | A-Award | A | Stock Option (Right to Buy) | 77,500 | 11.36 | 880.4K | 77,500 | — | ↗ |
| 2022-02-28 | Birznieks Gunther | Officer | A-Award | A | Stock Option (Right to Buy) | 77,500 | 11.36 | 880.4K | 77,500 | — | ↗ |
| 2021-12-01 | Polymeropoulos Mihael Hristos | Director / Officer | M-Exempt | A | Common Stock | 71,676 | 4.88 | 349.8K | 1,321,062 | — | ↗ |
| 2021-11-30 | Polymeropoulos Mihael Hristos | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 78,324 | 4.88 | 382.2K | 71,676 | — | ↗ |
| 2021-09-15 | Jones Aranthan II | Officer | M-Exempt | A | Common Stock | 7,842 | 11.32 | 88.8K | 98,804 | — | ↗ |
| 2021-09-09 | Mitchell Stephen Ray | Director | M-Exempt | A | Common Stock | 5,985 | 10.57 | 63.3K | 15,200 | — | ↗ |
| 2021-08-20 | Wijkstrom Joakim | Officer | S-Sale | D | Common Stock | 3,650 | 15.39 | 56.2K | 74,552 | — | ↗ |
| 2021-08-16 | Williams Timothy | Officer | S-Sale | D | Common Stock | 3,715 | 16.15 | 60.0K | 83,211 | — | ↗ |
| 2021-07-28 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 2,130 | 19.24 | 41.0K | 99,296 | — | ↗ |
| 2021-07-26 | Jones Aranthan II | Officer | S-Sale | D | Common Stock | 7,250 | 19.69 | 142.8K | 86,685 | — | ↗ |
| 2021-06-15 | Mitchell Stephen Ray | Director | M-Exempt | A | Common Stock | 4,015 | 10.57 | 42.4K | 14,215 | — | ↗ |
| 2021-06-14 | Chrousos Phaedra | Director | S-Sale | D | Common Stock | 2,075 | 19.34 | 40.1K | 12,925 | — | ↗ |
| 2021-06-10 | Watkins Thomas | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 54,505 | — | ↗ |
| 2021-06-10 | Ward Anne Sempowski | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 10,000 | — | ↗ |
| 2021-06-10 | Mitchell Stephen Ray | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 10,200 | — | ↗ |
| 2021-06-10 | DUGAN RICHARD W | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 19.21 | 192.1K | 10,000 | — | ↗ |
| 2021-06-10 | Chrousos Phaedra | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 19.21 | 192.1K | 10,000 | — | ↗ |
| 2021-03-15 | Jones Aranthan II | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 15,000 | 11.32 | 169.8K | 55,000 | — | ↗ |
| 2021-03-08 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 175,000 | 18.00 | 3.15M | 1,221,062 | — | ↗ |
| 2021-03-05 | Williams Timothy | Officer | S-Sale | D | Common Stock | 200 | 17.88 | 3.6K | 92,326 | — | ↗ |
| 2021-03-02 | Williams Timothy | Officer | S-Sale | D | Common Stock | 7,674 | 18.54 | 142.3K | 92,526 | — | ↗ |
| 2021-03-02 | Wijkstrom Joakim | Officer | S-Sale | D | Common Stock | 3,888 | 18.45 | 71.7K | 78,202 | — | ↗ |
| 2021-03-02 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 15,206 | 18.34 | 278.9K | 1,396,062 | — | ↗ |
| 2021-03-02 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 6,044 | 18.23 | 110.2K | 101,426 | — | ↗ |
| 2021-03-02 | Jones Aranthan II | Officer | S-Sale | D | Common Stock | 3,865 | 18.04 | 69.7K | 96,935 | — | ↗ |
| 2021-03-02 | Birznieks Gunther | Officer | S-Sale | D | Common Stock | 16,620 | 18.19 | 302.3K | 171,708 | — | ↗ |
| 2021-03-01 | Williams Timothy | Officer | S-Sale | D | Common Stock | 11,856 | 18.60 | 220.5K | 100,200 | — | ↗ |
| 2021-03-01 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 7,479 | 18.45 | 138.0K | 1,411,268 | — | ↗ |
| 2021-03-01 | Moran Kevin Patrick | Officer | S-Sale | D | Common Stock | 3,327 | 18.57 | 61.8K | 107,470 | — | ↗ |
| 2021-03-01 | Birznieks Gunther | Officer | S-Sale | D | Common Stock | 3,845 | 18.66 | 71.7K | 188,328 | — | ↗ |
| 2021-02-24 | Williams Timothy | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 77,500 | 20.28 | 1.57M | 77,500 | — | ↗ |
| 2021-02-24 | Wijkstrom Joakim | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 61,200 | 20.28 | 1.24M | 61,200 | — | ↗ |
| 2021-02-24 | Polymeropoulos Mihael Hristos | Director / Officer | A-Award | A | Employee Stock Option (Right to Buy) | 275,000 | 20.28 | 5.58M | 275,000 | — | ↗ |
| 2021-02-24 | Moran Kevin Patrick | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 77,500 | 20.28 | 1.57M | 77,500 | — | ↗ |
| 2021-02-24 | Jones Aranthan II | Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 22,499 | 12.27 | 276.1K | 37,501 | — | ↗ |
| 2021-02-24 | Birznieks Gunther | Officer | A-Award | A | Common Stock | 32,700 | 0.00 | — | 192,173 | — | ↗ |
| 2021-02-16 | Watkins Thomas | Director | M-Exempt | A | Common Stock | 15,000 | 7.11 | 106.7K | 55,323 | — | ↗ |
| 2021-02-16 | DUGAN RICHARD W | Director | M-Exempt | A | Common Stock | 15,000 | 7.11 | 106.7K | 60,641 | — | ↗ |
| 2020-12-15 | Polymeropoulos Mihael Hristos | Director / Officer | M-Exempt | A | Common Stock | 46,663 | 8.75 | 408.3K | 1,342,897 | — | ↗ |
| 2020-12-14 | Polymeropoulos Mihael Hristos | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 61,520 | 8.75 | 538.3K | 46,663 | — | ↗ |
| 2020-12-11 | Polymeropoulos Mihael Hristos | Director / Officer | M-Exempt | A | Common Stock | 41,817 | 8.75 | 365.9K | 1,320,816 | — | ↗ |
| 2020-08-20 | Wijkstrom Joakim | Officer | S-Sale | D | Common Stock | 3,710 | 11.08 | 41.1K | 56,290 | — | ↗ |
| 2020-08-14 | Williams Timothy | Officer | S-Sale | D | Common Stock | 3,684 | 11.81 | 43.5K | 79,356 | — | ↗ |
| 2020-08-12 | Jones Aranthan II | Officer | S-Sale | D | Common Stock | 7,200 | 11.81 | 85.0K | 75,487 | — | ↗ |
| 2020-07-27 | Moran Kevin Patrick | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 10.83 | 974.7K | 90,000 | — | ↗ |
| 2020-07-27 | Jones Aranthan II | Officer | S-Sale | D | Common Stock | 7,313 | 10.62 | 77.6K | 82,687 | — | ↗ |
| 2020-06-11 | Watkins Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 10.57 | 105.7K | 10,000 | — | ↗ |
| 2020-06-11 | Ward Anne Sempowski | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2020-06-11 | Mitchell Stephen Ray | Director | A-Award | A | Stock Option (right to buy) | 10,000 | 10.57 | 105.7K | 10,000 | — | ↗ |
| 2020-06-11 | DUGAN RICHARD W | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 10.57 | 105.7K | 10,000 | — | ↗ |
| 2020-06-11 | Chrousos Phaedra | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 10.57 | 105.7K | 10,000 | — | ↗ |
| 2020-05-29 | Watkins Thomas | Director | M-Exempt | A | Common Stock | 15,000 | 7.38 | 110.7K | 45,000 | — | ↗ |
| 2020-05-28 | DUGAN RICHARD W | Director | M-Exempt | A | Common Stock | 15,000 | 7.38 | 110.7K | 50,770 | — | ↗ |
| 2020-03-15 | Moran Kevin Patrick | Officer | — | I | Common Stock | 0 | 0.00 | — | 635 | — | ↗ |
| 2020-03-03 | Williams Timothy | Officer | S-Sale | D | Common Stock | 1,237 | 10.51 | 13.0K | 83,040 | — | ↗ |
| 2020-03-03 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 5,152 | 10.98 | 56.5K | 1,278,999 | — | ↗ |
| 2020-03-03 | Kelly James Patrick | Officer | S-Sale | D | Common Stock | 5,889 | 10.76 | 63.4K | 186,869 | — | ↗ |
| 2020-03-03 | Birznieks Gunther | Officer | S-Sale | D | Common Stock | 5,535 | 10.66 | 59.0K | 159,473 | — | ↗ |
| 2020-03-02 | Williams Timothy | Officer | S-Sale | D | Common Stock | 3,148 | 10.30 | 32.4K | 84,277 | — | ↗ |
| 2020-03-02 | Reverberi Gian Piero | Officer | S-Sale | D | Common Stock | 1,450 | 10.18 | 14.8K | 165,384 | — | ↗ |
| 2020-03-02 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 10,428 | 10.57 | 110.2K | 1,284,151 | — | ↗ |
| 2020-03-02 | Kelly James Patrick | Officer | S-Sale | D | Common Stock | 12,968 | 10.19 | 132.1K | 192,758 | — | ↗ |
| 2020-03-02 | Birznieks Gunther | Officer | S-Sale | D | Common Stock | 12,223 | 10.04 | 122.7K | 165,008 | — | ↗ |
| 2020-02-26 | Williams Timothy | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 70,000 | 11.32 | 792.4K | 70,000 | — | ↗ |
| 2020-02-26 | Wijkstrom Joakim | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 60,000 | — | ↗ |
| 2020-02-26 | Polymeropoulos Mihael Hristos | Director / Officer | A-Award | A | Common Stock | 60,000 | 0.00 | — | 1,294,579 | — | ↗ |
| 2020-02-26 | Jones Aranthan II | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 70,000 | 11.32 | 792.4K | 70,000 | — | ↗ |
| 2020-02-26 | Birznieks Gunther | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 70,000 | 11.32 | 792.4K | 70,000 | — | ↗ |
| 2020-02-14 | Mitchell Stephen Ray | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 12.70 | 444.5K | 35,000 | — | ↗ |
| 2020-01-02 | Reverberi Gian Piero | Officer | S-Sale | D | Common Stock | 1,155 | 16.06 | 18.6K | 166,834 | — | ↗ |
| 2020-01-02 | Polymeropoulos Mihael Hristos | Director / Officer | S-Sale | D | Common Stock | 9,467 | 16.00 | 151.5K | 1,234,579 | — | ↗ |
| 2020-01-02 | Kelly James Patrick | Officer | S-Sale | D | Common Stock | 4,020 | 15.94 | 64.1K | 205,726 | — | ↗ |
| 2020-01-02 | Birznieks Gunther | Officer | S-Sale | D | Common Stock | 4,020 | 15.93 | 64.0K | 147,231 | — | ↗ |
| 2019-12-12 | Polymeropoulos Mihael Hristos | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 85,801 | 10.65 | 913.8K | 0 | — | ↗ |
| 2019-12-11 | Polymeropoulos Mihael Hristos | Director / Officer | M-Exempt | D | Employee Stock Option (Right to Buy) | 89,199 | 10.65 | 950.0K | 85,801 | — | ↗ |
| 2019-10-28 | Ward Anne Sempowski | Director | A-Award | A | Stock Option (right to buy) | 35,000 | 14.21 | 497.4K | 35,000 | — | ↗ |
| 2019-08-26 | DUGAN RICHARD W | Director | M-Exempt | A | Common Stock | 15,000 | 14.78 | 221.7K | 50,770 | — | ↗ |
| 2019-08-19 | Wijkstrom Joakim | Officer | A-Award | A | Stock Option (Right to Buy) | 90,000 | 15.33 | 1.38M | 90,000 | — | ↗ |
| 2019-08-19 | Jones Aranthan II | Officer | — | D | Stock Option (Right to Buy) | 60,000 | 12.27 | 736.2K | 0 | — | ↗ |
| 2019-08-14 | Williams Timothy | Officer | S-Sale | D | Common Stock | 2,575 | 14.69 | 37.8K | 57,425 | — | ↗ |
| 2019-06-13 | Watkins Thomas | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 30,000 | — | ↗ |
| 2019-06-13 | DUGAN RICHARD W | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 35,770 | — | ↗ |
| 2019-06-13 | Chrousos Phaedra | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 15.04 | 150.4K | 10,000 | — | ↗ |
| 2019-06-13 | COLA MICHAEL F | Director | A-Award | A | Common Stock | 5,000 | 0.00 | — | 15,000 | — | ↗ |
| 2019-05-21 | Polymeropoulos Mihael Hristos | Director / Officer | M-Exempt | A | Common Stock | 79,019 | 12.55 | 991.7K | 1,284,327 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-410.8K
Shares Outstanding
59.11M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Mihael H. Polymeropoulos, M.D. President, Chief Executive Officer and Chairman of the Board | 965.7K | — | 2.01M | — | 834.3K | 44.5K | 3.85M | 52.11% | ↗ |
| 2 | 2025 | Joakim Wijkstrom Senior Vice President, Chief Marketing Officer | 579.6K | — | 557.5K | — | 281.7K | 38.7K | 1.46M | 38.25% | ↗ |
| 3 | 2025 | Timothy Williams Senior Vice President, General Counsel and Secretary | 559.9K | — | 557.5K | — | 272.1K | 55.4K | 1.44M | 38.58% | ↗ |
| 4 | 2025 | Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer | 559.9K | — | 557.5K | — | 272.1K | 50.1K | 1.44M | 38.72% | ↗ |
| 5 | 2025 | Gunther Birznieks Senior Vice President, Business Development | 559.9K | — | 557.5K | — | 272.1K | 25.9K | 1.42M | 39.39% | ↗ |
| 6 | 2024 | Mihael H. Polymeropoulos, M.D. President, Chief Executive Officer and Chairman of the Board | 933.0K | — | 1.97M | — | 947.9K | 44.3K | 3.90M | 50.59% | ↗ |
| 7 | 2024 | Timothy Williams Senior Vice President, General Counsel and Secretary | 541.0K | — | 547.5K | — | 309.2K | 55.4K | 1.45M | 37.68% | ↗ |
| 8 | 2024 | Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer | 541.0K | — | 547.5K | — | 309.2K | 49.9K | 1.45M | 37.82% | ↗ |
| 9 | 2024 | Gunther Birznieks Senior Vice President, Business Development | 541.0K | — | 547.5K | — | 309.2K | 25.8K | 1.42M | 38.46% | ↗ |
| 10 | 2024 | Joakim Wijkstrom Senior Vice President, Chief Marketing Officer | 560.0K | — | 143.2K | — | 320.0K | 38.0K | 1.06M | 13.50% | ↗ |
| 11 | 2023 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 897.0K | — | 810.8K | 988.6K | 983.1K | 40.7K | 3.72M | 48.37% | ↗ |
| 12 | 2023 | Mihael H. Polymeropoulos, M.D. President, Chief Executive Officer and Chairman of the Board | 897.0K | — | 810.8K | 988.6K | 983.1K | 40.7K | 3.72M | 48.37% | ↗ |
| 13 | 2023 | Timothy Williams Senior Vice President, General Counsel and Secretary | 520.0K | — | 230.5K | 278.6K | 320.6K | 50.1K | 1.40M | 36.37% | ↗ |
| 14 | 2023 | Timothy Williams Senior Vice President, General Counsel and Secretary | 520.0K | — | 230.5K | 278.6K | 320.6K | 50.1K | 1.40M | 36.37% | ↗ |
| 15 | 2023 | Gunther Birznieks Senior Vice President, Business Development | 520.0K | — | 230.5K | 278.6K | 320.6K | 23.3K | 1.37M | 37.08% | ↗ |
| 16 | 2023 | Gunther Birznieks Senior Vice President, Business Development | 520.0K | — | 230.5K | 278.6K | 320.6K | 23.3K | 1.37M | 37.08% | ↗ |
| 17 | 2023 | Joakim Wijkstrom Senior Vice President, Chief Marketing Officer | 560.0K | — | 230.5K | 278.6K | 252.0K | 34.3K | 1.36M | 37.56% | ↗ |
| 18 | 2023 | Joakim Wijkstrom Senior Vice President, Chief Marketing Officer | 560.0K | — | 230.5K | 278.6K | 252.0K | 34.3K | 1.36M | 37.56% | ↗ |
| 19 | 2023 | Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer | 477.0K | — | 230.5K | 278.6K | 294.1K | 44.5K | 1.32M | 38.44% | ↗ |
| 20 | 2023 | Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer | 477.0K | — | 230.5K | 278.6K | 294.1K | 44.5K | 1.32M | 38.44% | ↗ |
| 21 | 2022 | Mihael H. Polymeropoulos, M.D. President, Chief Executive Officer and Chairman of the Board | 815.1K | — | 1.31M | 1.45M | 658.6K | 37.9K | 4.27M | 64.59% | ↗ |
| 22 | 2022 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 815.1K | — | 1.31M | 1.45M | 658.6K | 37.9K | 4.27M | 64.59% | ↗ |
| 23 | 2022 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 815.1K | — | 1.31M | 1.45M | 658.6K | 37.9K | 4.27M | 64.59% | ↗ |
| 24 | 2022 | Joakim Wijkstrom Senior Vice President, Chief Marketing Officer | 553.3K | — | 371.5K | 409.0K | 251.5K | 31.6K | 1.62M | 48.27% | ↗ |
| 25 | 2022 | Joakim Wijkstrom Senior Vice President, Chief Marketing Officer | 553.3K | — | 371.5K | 409.0K | 251.5K | 31.6K | 1.62M | 48.27% | ↗ |
| 26 | 2022 | Timothy Williams Senior Vice President, General Counsel and Secretary | 466.4K | — | 371.5K | 409.0K | 212.0K | 46.0K | 1.50M | 51.86% | ↗ |
| 27 | 2022 | Timothy Williams Senior Vice President, General Counsel and Secretary | 466.4K | — | 371.5K | 409.0K | 212.0K | 46.0K | 1.50M | 51.86% | ↗ |
| 28 | 2022 | Gunther Birznieks Senior Vice President, Business Development | 460.0K | — | 371.5K | 409.0K | 209.1K | 21.7K | 1.47M | 53.05% | ↗ |
| 29 | 2022 | Gunther Birznieks Senior Vice President, Business Development | 460.0K | — | 371.5K | 409.0K | 209.1K | 21.7K | 1.47M | 53.05% | ↗ |
| 30 | 2022 | Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer | 426.1K | — | 371.5K | 409.0K | 193.7K | 40.4K | 1.44M | 54.17% | ↗ |
| 31 | 2022 | Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer | 426.1K | — | 371.5K | 409.0K | 193.7K | 40.4K | 1.44M | 54.17% | ↗ |
| 32 | 2021 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 769.0K | — | 2.33M | 2.46M | 596.7K | 36.1K | 6.19M | 77.37% | ↗ |
| 33 | 2021 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 769.0K | — | 2.33M | 2.46M | 596.7K | 36.1K | 6.19M | 77.37% | ↗ |
| 34 | 2021 | Timothy Williams Senior Vice President, General Counsel and Secretary | 440.0K | — | 663.2K | 693.3K | 192.1K | 43.6K | 2.03M | 66.75% | ↗ |
| 35 | 2021 | Timothy Williams Senior Vice President, General Counsel and Secretary | 440.0K | — | 663.2K | 693.3K | 192.1K | 43.6K | 2.03M | 66.75% | ↗ |
| 36 | 2021 | Gunther Birznieks Senior Vice President, Business Development | 434.0K | — | 663.2K | 693.3K | 189.4K | 21.0K | 2.00M | 67.79% | ↗ |
| 37 | 2021 | Gunther Birznieks Senior Vice President, Business Development | 434.0K | — | 663.2K | 693.3K | 189.4K | 21.0K | 2.00M | 67.79% | ↗ |
| 38 | 2021 | Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer | 402.0K | — | 663.2K | 693.3K | 175.5K | 38.0K | 1.97M | 68.79% | ↗ |
| 39 | 2021 | Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer | 402.0K | — | 663.2K | 693.3K | 175.5K | 38.0K | 1.97M | 68.79% | ↗ |
| 40 | 2021 | Joakim Wijkstrom Senior Vice President, Chief Marketing Officer | 522.0K | — | 523.2K | 547.5K | 227.9K | 29.8K | 1.85M | 57.86% | ↗ |
| 41 | 2021 | Joakim Wijkstrom Senior Vice President, Chief Marketing Officer | 522.0K | — | 523.2K | 547.5K | 227.9K | 29.8K | 1.85M | 57.86% | ↗ |
| 42 | 2020 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 746.2K | — | 679.2K | 795.8K | 656.7K | 35.5K | 2.91M | 50.63% | ↗ |
| 43 | 2020 | Joakim Wijkstrom Senior Vice President, Chief Marketing Officer | 506.4K | — | 339.6K | 397.9K | 250.7K | 29.3K | 1.52M | 48.40% | ↗ |
| 44 | 2020 | Timothy Williams Senior Vice President, General Counsel and Secretary | 400.0K | — | 339.6K | 397.9K | 200.0K | 41.5K | 1.38M | 53.48% | ↗ |
| 45 | 2020 | Aranthan "AJ" Jones II Chief Corporate Affairs and Communications Officer | 406.1K | — | 339.6K | 397.9K | 201.0K | 33.7K | 1.38M | 53.51% | ↗ |
| 46 | 2020 | Gunther Birznieks Senior Vice President, Business Development | 421.0K | — | 339.6K | 397.9K | 200.0K | 19.3K | 1.38M | 53.53% | ↗ |
| 47 | 2020 | Kevin Moran Senior Vice President, Chief Financial Officer and Treasurer | 324.7K | — | 331.1K | 427.8K | 200.0K | 36.1K | 1.32M | 57.50% | ↗ |
| 48 | 2020 | James P. Kelly Former Executive Vice President, Chief Financial Officer and Treasurer | 124.1K | — | — | — | — | 16.2K | 140.3K | 0.00% | ↗ |
| 49 | 2019 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 721.0K | — | 1.24M | 1.61M | 675.0K | 34.8K | 4.28M | 66.56% | ↗ |
| 50 | 2019 | Gian Piero Reverberi Former Senior Vice President, Chief Commercial Officer | 519.1K | — | 618.6K | 805.1K | 273.3K | 80.3K | 2.30M | 62.00% | ↗ |
| 51 | 2019 | James P. Kelly Former Executive Vice President, Chief Financial Officer and Treasurer | 493.4K | — | 618.6K | 805.1K | 288.6K | 42.7K | 2.25M | 63.32% | ↗ |
| 52 | 2019 | Timothy Williams Senior Vice President, General Counsel and Secretary | 379.3K | — | 618.6K | 805.1K | 177.5K | 42.3K | 2.02M | 70.38% | ↗ |
| 53 | 2019 | Gunther Birznieks Senior Vice President, Business Development | 386.3K | — | 618.6K | 805.1K | 180.8K | 20.1K | 2.01M | 70.80% | ↗ |
| 54 | 2018 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 700.0K | — | 1.13M | 1.46M | 700.0K | 37.3K | 4.02M | 64.29% | ↗ |
| 55 | 2018 | James P. Kelly Former Executive Vice President, Chief Financial Officer and Treasurer | 479.0K | — | 754.0K | 832.2K | 299.4K | 36.8K | 2.40M | 66.05% | ↗ |
| 56 | 2018 | Gian Piero Reverberi Senior Vice President, Chief Commercial Officer | 495.3K | — | 618.6K | 805.1K | 278.6K | 78.3K | 2.28M | 62.55% | ↗ |
| 57 | 2018 | James P. Kelly Executive Vice President, Chief Financial Officer and Treasurer | 479.0K | — | 618.6K | 805.1K | 299.4K | 36.8K | 2.24M | 63.59% | ↗ |
| 58 | 2018 | Gian Piero Reverberi Former Senior Vice President, Chief Commercial Officer | 495.3K | — | 565.5K | 728.2K | 278.6K | 78.3K | 2.15M | 60.29% | ↗ |
| 59 | 2018 | Timothy Williams Senior Vice President, General Counsel and Secretary | 144.9K | 40.0K | 643.5K | 1.09M | 71.9K | 15.7K | 2.00M | 86.40% | ↗ |
| 60 | 2018 | Gunther Birznieks Senior Vice President, Business Development | 375.0K | — | 565.5K | 728.2K | 187.5K | 16.8K | 1.87M | 69.07% | ↗ |
| 61 | 2017 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 675.0K | — | 2.90M | 2.16M | 502.2K | 32.8K | 6.27M | 80.69% | ↗ |
| 62 | 2017 | James P. Kelly Executive Vice President, Chief Financial Officer and Treasurer | 465.0K | — | 754.0K | 832.2K | 216.2K | 31.3K | 2.30M | 69.00% | ↗ |
| 63 | 2017 | James P. Kelly Former Executive Vice President, Chief Financial Officer and Treasurer | 465.0K | — | 1.02M | 548.8K | 216.2K | 31.3K | 2.28M | 68.70% | ↗ |
| 64 | 2017 | Gunther Birznieks Senior Vice President, Business Development | 325.0K | — | 1.02M | 548.8K | 195.0K | 15.0K | 2.10M | 74.51% | ↗ |
| 65 | 2017 | Gian Piero Reverberi Senior Vice President, Chief Commercial Officer | 486.6K | — | 565.5K | 728.2K | 203.6K | 81.6K | 2.07M | 62.63% | ↗ |
| 66 | 2017 | Gian Piero Reverberi Senior Vice President, Chief Commercial Officer | 486.6K | — | 565.5K | 728.2K | 203.6K | 81.6K | 2.07M | 62.63% | ↗ |
| 67 | 2017 | Richard L. Gulino Senior Vice President, General Counsel and Secretary | 345.0K | — | 565.5K | 728.2K | 128.3K | 25.9K | 1.79M | 72.16% | ↗ |
| 68 | 2017 | Gian Piero Reverberi Former Senior Vice President, Chief Commercial Officer | 486.6K | — | 435.0K | 548.8K | 203.6K | 81.6K | 1.76M | 56.04% | ↗ |
| 69 | 2016 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 618.0K | — | 2.90M | 2.16M | 1.48M | 28.3K | 7.19M | 70.36% | ↗ |
| 70 | 2016 | James P. Kelly Executive Vice President, Chief Financial Officer and Treasurer | 390.0K | — | 1.02M | 548.8K | 202.8K | 32.4K | 2.19M | 71.44% | ↗ |
| 71 | 2016 | Gian Piero Reverberi Senior Vice President, Chief Commercial Officer | 472.2K | — | 435.0K | 548.8K | 212.5K | 66.0K | 1.73M | 56.72% | ↗ |
| 72 | 2016 | Gian Piero Reverberi Senior Vice President, Chief Commercial Officer | 472.2K | — | 435.0K | 548.8K | 212.5K | 66.0K | 1.73M | 56.72% | ↗ |
| 73 | 2016 | Richard L. Gulino Senior Vice President, General Counsel and Secretary | 325.0K | — | 435.0K | 548.8K | 195.0K | 24.9K | 1.53M | 64.36% | ↗ |
| 74 | 2016 | Richard L. Gulino Senior Vice President, General Counsel and Secretary | 325.0K | — | 435.0K | 548.8K | 195.0K | 24.9K | 1.53M | 64.36% | ↗ |
| 75 | 2016 | Paolo Baroldi, M.D., Ph.D. Former Senior Vice President, Chief Medical Officer | 386.0K | — | — | — | 177.6K | 35.3K | 598.8K | 0.00% | ↗ |
| 76 | 2015 | Richard L. Gulino Senior Vice President, General Counsel and Secretary | 97.3K | — | 901.2K | 1.40M | 130.0K | 39.9K | 2.56M | 89.58% | ↗ |
| 77 | 2015 | Richard L. Gulino Senior Vice President, General Counsel and Secretary | 97.3K | — | 901.2K | 1.40M | 130.0K | 39.9K | 2.56M | 89.58% | ↗ |
| 78 | 2015 | Gian Piero Reverberi Senior Vice President, Chief Commercial Officer | 146.9K | — | 872.2K | 1.35M | 66.7K | 13.0K | 2.45M | 90.74% | ↗ |
| 79 | 2015 | Gian Piero Reverberi Senior Vice President, Chief Commercial Officer | 145.1K | — | 872.2K | 1.35M | 65.0K | 12.7K | 2.44M | 90.88% | ↗ |
| 80 | 2015 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 600.0K | — | 595.5K | 756.0K | 396.0K | 19.2K | 2.37M | 57.10% | ↗ |
| 81 | 2015 | Thomas E. Gibbs Former Senior Vice President, Chief Commercial Officer | 268.8K | — | 603.0K | 997.5K | 150.0K | 32.6K | 2.05M | 78.00% | ↗ |
| 82 | 2015 | James P. Kelly Executive Vice President, Chief Financial Officer and Treasurer | 375.0K | — | 238.2K | 302.4K | 210.0K | 19.5K | 1.15M | 47.21% | ↗ |
| 83 | 2015 | James P. Kelly Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 375.0K | — | 238.2K | 302.4K | 210.0K | 19.5K | 1.15M | 47.21% | ↗ |
| 84 | 2015 | Paolo Baroldi, M.D., Ph.D. Senior Vice President, Chief Medical Officer | 375.0K | — | 238.2K | 302.4K | 180.0K | 23.6K | 1.12M | 48.30% | ↗ |
| 85 | 2015 | Paolo Baroldi, M.D., Ph.D. Former Senior Vice President, Chief Medical Officer | 375.0K | — | 238.2K | 302.4K | 180.0K | 23.6K | 1.12M | 48.30% | ↗ |
| 86 | 2014 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 580.0K | — | 613.5K | 1.05M | 435.0K | 18.8K | 2.70M | 61.72% | ↗ |
| 87 | 2014 | Paolo Baroldi, M.D., Ph.D. Senior Vice President, Chief Medical Officer | 360.0K | — | 245.4K | 421.2K | 180.0K | 22.5K | 1.23M | 54.24% | ↗ |
| 88 | 2014 | Paolo Baroldi, M.D., Ph.D. Former Senior Vice President, Chief Medical Officer | 360.0K | — | 245.4K | 421.2K | 180.0K | 22.5K | 1.23M | 54.24% | ↗ |
| 89 | 2014 | James P. Kelly Executive Vice President, Chief Financial Officer and Treasurer | 360.0K | — | 245.4K | 421.2K | 180.0K | 19.6K | 1.23M | 54.36% | ↗ |
| 90 | 2014 | James P. Kelly Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 360.0K | — | 245.4K | 421.2K | 180.0K | 19.6K | 1.23M | 54.36% | ↗ |
| 91 | 2014 | Robert Repella Former Senior Vice President and Chief Commercial Officer | — | — | — | 53.9K | — | 544.0K | 597.9K | 9.01% | ↗ |
| 92 | 2013 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 515.0K | — | 579.5K | 1.05M | 354.1K | 22.1K | 2.52M | 64.64% | ↗ |
| 93 | 2013 | James P. Kelly Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 315.0K | — | 231.8K | 419.8K | 157.5K | 21.2K | 1.15M | 56.89% | ↗ |
| 94 | 2013 | Paolo Baroldi, M.D., Ph.D. Senior Vice President, Chief Medical Officer | 279.8K | — | 231.8K | 419.8K | 160.0K | 19.9K | 1.11M | 58.63% | ↗ |
| 95 | 2013 | Robert Repella Senior Vice President, Chief Commercial Officer Paolo Baroldi, M.D., Ph.D. Senior Vice President, Chief Medical Officer | 279.8K | — | 231.8K | 419.8K | 160.0K | 19.9K | 1.11M | 58.63% | ↗ |
| 96 | 2013 | Robert Repella Former Senior Vice President and Chief Commercial Officer | 368.0K | — | — | — | 147.2K | 70.1K | 585.3K | 0.00% | ↗ |
| 97 | 2012 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 500.0K | — | 156.0K | 284.2K | 300.0K | 18.1K | 1.26M | 34.98% | ↗ |
| 98 | 2012 | John J. Feeney III, M.D. former Senior Vice President and Chief Medical Officer | 224.2K | — | — | — | — | 496.2K | 720.4K | 0.00% | ↗ |
| 99 | 2012 | Robert Repella Former Senior Vice President and Chief Commercial Officer | 350.0K | — | 58.5K | 106.6K | 168.0K | 24.8K | 707.8K | 23.32% | ↗ |
| 100 | 2012 | James P. Kelly Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 300.0K | — | 58.5K | 106.6K | 144.0K | 17.8K | 626.9K | 26.33% | ↗ |
| 101 | 2011 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 485.6K | — | 244.0K | 456.5K | 291.0K | 7.4K | 1.48M | 47.19% | ↗ |
| 102 | 2011 | Robert Repella Senior Vice President, Chief Commercial Officer | 66.4K | — | 354.0K | — | — | — | 1.27M | 27.89% | ↗ |
| 103 | 2011 | John J. Feeney III, M.D. former Senior Vice President and Chief Medical Officer | 310.4K | — | 91.5K | 171.2K | 130.2K | 7.4K | 710.7K | 36.97% | ↗ |
| 104 | 2011 | James P. Kelly Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 285.6K | — | 91.5K | 171.2K | 136.8K | 7.4K | 692.5K | 37.94% | ↗ |
| 105 | 2010 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 461.1K | — | 1.31M | — | 391.0K | 7.4K | 2.99M | 43.89% | ↗ |
| 106 | 2010 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 461.1K | — | 1.31M | 818.8K | 391.0K | 7.4K | 2.99M | 71.26% | ↗ |
| 107 | 2010 | John J. Feeney III, M.D. former Senior Vice President and Chief Medical Officer | 281.3K | — | 514.2K | 307.0K | 117.6K | 7.4K | 1.23M | 66.90% | ↗ |
| 108 | 2010 | John J. Feeney III, M.D. Chief Medical Officer | 281.3K | — | 514.2K | — | 117.6K | 7.4K | 1.23M | 41.89% | ↗ |
| 109 | 2010 | James P. Kelly Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 15.2K | — | 413.5K | 773.9K | — | — | 1.20M | 98.74% | ↗ |
| 110 | 2010 | James P. Kelly Senior Vice President, Chief Financial Officer, Treasurer and Secretary | 15.2K | — | 413.5K | — | — | — | 1.20M | 34.39% | ↗ |
| 111 | 2010 | Stephanie R. Irish former Acting Chief Financial Officer, Treasurer and Secretary | 137.5K | — | 350.1K | — | — | 4.1K | 491.7K | 71.20% | ↗ |
| 112 | 2010 | William D. “Chip” Clark former Senior Vice President, Chief Business Officer and Secretary | 90.3K | — | 350.1K | — | — | 2.7K | 443.1K | 79.02% | ↗ |
| 113 | 2009 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 442.6K | — | — | — | 530.4K | 7.4K | 4.13M | 0.00% | ↗ |
| 114 | 2009 | John J. Feeney III, M.D. Chief Medical Officer | 250.7K | — | — | — | 162.0K | 7.4K | 1.64M | 0.00% | ↗ |
| 115 | 2009 | William D. “Chip” Clark former Senior Vice President, Chief Business Officer and Secretary | 312.5K | — | — | — | 187.2K | 7.4K | 1.57M | 0.00% | ↗ |
| 116 | 2009 | Stephanie R. Irish former Acting Chief Financial Officer, Treasurer and Secretary | 183.0K | — | — | — | 120.0K | 5.4K | 1.53M | 0.00% | ↗ |
| 117 | 2009 | William D. “Chip” Clark Senior Vice President, Chief Business Officer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 118 | 2009 | John J. Feeney III, M.D. Acting Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 119 | 2009 | Paolo Baroldi, M.D., Ph.D. Former Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 120 | 2009 | Steven A. Shallcross Former Senior Vice President, Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 121 | 2009 | James P. Kelly Senior Vice President, Chief Financial Officer, Treasurer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 122 | 2009 | Stephanie R. Irish Acting Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 123 | 2008 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | 442.0K | — | 42.8K | — | — | 6.9K | 1.42M | 3.01% | ↗ |
| 124 | 2008 | William D. “Chip” Clark former Senior Vice President, Chief Business Officer and Secretary | 312.0K | — | 14.3K | — | — | 6.9K | 778.2K | 1.83% | ↗ |
| 125 | 2008 | Albert W. Gianchetti Senior Vice President and Chief | — | — | — | — | — | — | — | — | ↗ |
| 126 | 2008 | James P. Kelly Senior Vice President, Chief Financial Officer, Treasurer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 127 | 2008 | John J. Feeney III, M.D. Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 128 | 2008 | Stephanie R. Irish former Acting Chief Financial Officer, Treasurer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 129 | 2008 | John J. Feeney III, M.D. Acting Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 130 | 2008 | Paolo Baroldi, M.D., Ph.D. Former Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 131 | 2008 | Steven A. Shallcross Former Senior Vice President, Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 132 | 2008 | Stephanie R. Irish Acting Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 133 | 2008 | William D. “Chip” Clark Senior Vice President, Chief Business Officer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 134 | 2008 | Steven A. Shallcross Senior Vice President, Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 135 | 2008 | Paolo Baroldi, M.D., Ph.D. Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 136 | 2007 | Albert W. Gianchetti | — | — | — | — | — | — | — | — | ↗ |
| 137 | 2007 | Paolo Baroldi, M.D., Ph.D. Former Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 138 | 2007 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 139 | 2007 | Paolo Baroldi, M.D., Ph.D. Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 140 | 2007 | Albert W. Gianchetti Senior Vice President and Chief | — | — | — | — | — | — | — | — | ↗ |
| 141 | 2007 | Stephanie R. Irish Acting Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 142 | 2007 | Steven A. Shallcross Former Senior Vice President, Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 143 | 2007 | Steven A. Shallcross Senior Vice President, Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 144 | 2007 | William D. “Chip” Clark Senior Vice President, Chief Business Officer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 145 | 2006 | Mihael H. Polymeropoulos, M.D. President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 146 | 2006 | William D. “Chip” Clark Senior Vice President, Chief Business Officer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 147 | 2006 | Paolo Baroldi, M.D., Ph.D. Senior Vice President and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 148 | 2006 | Steven A. Shallcross Senior Vice President, Chief Financial Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Mihael H. Polymeropoulos | Founder, President, Chief Executive Officer & Chairman of The Board | 2M | — |
| Timothy Williams | Senior Vice President, General Counsel & Secretary | 905.6K | male |
| Joakim Wijkstrom | Senior Vice President & Chief Marketing Officer | 900.0K | male |
| Kevin Patrick Moran | Senior Vice President, Chief Financial Officer & Treasurer | 882.2K | male |
| Gunther Birznieks | Senior Vice President of Business Development | 858.0K | male |
| Scott L. Howell | Chief People Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VNDA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
